Allovir Files 2025 Proxy Statement

TL;DR

Allovir's 2025 proxy is out - vote by Jan 9th on leadership & strategy.

AI Summary

Allovir, Inc. filed its Definitive Proxy Statement (DEF 14A) on December 6, 2024, for its 2025 annual meeting of stockholders, scheduled for January 9, 2025. The filing details the company's governance and proposals to be voted on by shareholders. Allovir, formerly ViraCyte, Inc., is a biotechnology company focused on developing allogeneic T-cell therapies.

Why It Matters

This filing provides shareholders with crucial information about the company's leadership, executive compensation, and key proposals, enabling informed voting decisions that can impact the company's strategic direction and financial performance.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine disclosures, but the specific proposals and company performance discussed within can carry significant risk.

Key Numbers

• 2025 — Fiscal Year End (The proxy statement pertains to the company's operations and governance for the upcoming fiscal year.)

Key Players & Entities

• Allovir, Inc. (company) — Registrant
• ViraCyte, Inc. (company) — Former company name
• December 6, 2024 (date) — Filing date
• January 9, 2025 (date) — Annual meeting date

FAQ

Key Financial Figures

• $0.0001 — nding shares of common stock, par value $0.0001 per share (Common Stock), including any
• $10,500 — nal support, for services fees of up to $10,500 and the reimbursement of certain expens

Filing Documents

• d902309ddef14a.htm (DEF 14A) — 182KB
• g902309g01g29.jpg (GRAPHIC) — 180KB
• g902309g09i09.jpg (GRAPHIC) — 28KB
• g902309g30g30.jpg (GRAPHIC) — 166KB
• 0001193125-24-271972.txt ( ) — 692KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 6 PROPOSAL 1 APPROVAL OF AN AMENDMENT TO OUR THIRD AMENDED AND RESTATED CERTIFICATE TO EFFECT THE REVERSE STOCK SPLIT 10 PROPOSAL 2 TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES AT THE TIME OF THE SPECIAL MEETING TO APPROVE THE REVERSE STOCK SPLIT PROPOSAL 20 STOCKHOLDER PROPOSALS AND NOMINATIONS 21 OTHER MATTERS 22 AVAILABILITY OF CERTAIN DOCUMENTS 23 ANNEX A: CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALLOVIR, INC. A-1 Table of Contents PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON JANUARY 9, 2025 QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING OF STOCKHOLDERS PROXY STATEMENT SPECIAL MEETING OF STOCKHOLDERS This proxy statement contains information about the Special Meeting of Stockholders (the Special Meeting) of AlloVir, Inc., a Delaware corporation, including any postponements or adjournments of the Special Meeting. The Special Meeting will be held on January 9, 2025, at 9:00 A.M., Eastern Time via live webcast. The proxy materials can be accessed by following the instructions in the Notice (www.proxyvote.com) as well as online at our Investor Relations website at https://ir.allovir.com. In this proxy statement, we sometimes refer to AlloVir, Inc. and its subsidiaries as AlloVir, the Company, we, us, or our. In addition, unless the context otherwise requires, references to stockholders are to the holders of our common stock, par value $0.0001 per share (Common Stock). This proxy statement contains important information for you to consider when deciding how to vote on the matters for which we are soliciting proxies. Please read it carefully. What Proposals Will Be Presented at the Special Meeting and What Are the Voting Recommendations of the Board of Directors? The proposals that will be presented at the

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT Except where specifically noted, the following information and all other information contained in this proxy statement does not give effect to the Reverse Stock Split. The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of November 22, 2024 by: each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of our capital stock; each of our named executive officers; each of our directors; and all of our executive officers and directors as a group. Beneficial ownership is determined in accordance with the rules of the SEC. A person is deemed to be a beneficial holder of our capital stock if that person has or shares voting power, which includes the power to vote or direct the voting of our capital stock, or investment power, which includes the power to dispose of or to direct the disposition of such capital stock. Except as noted by footnote, and beneficially owned by them. The table lists applicable percentage ownership based on 115,563,283 shares of common stock outstanding as of November 22, 2024. Unless otherwise noted below, the address of each person listed on the table is c/o AlloVir, Inc., PO Box 44, 1661 Massachusetts Avenue, Lexington, MA 02420. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to restricted stock units and options held by that person that are currently exercisable or exercisable within 60 days after November 22, 2024. We did not deem these shares outstanding, however, for the purpose of computing th

View Full Filing

View this DEF 14A filing on SEC EDGAR